Foreign giants conduct intensive research on innovative drugs in China.

Currently, investment opportunities in the field of innovative drugs in China are attracting more and more attention from international capital. Data shows that since the second half of the year, many Chinese innovative drug companies including BeiGene and BeiLiTianHeng have been visited intensively by foreign investors. Among the foreign institutions conducting research, there is also the asset management company Point72, known as the "craziest money-making machine on Wall Street." At this point in time, many foreign institutions believe that the Chinese innovative drug industry is experiencing multiple positive factors, including improvements in research and development capabilities, policy support, opportunities for expansion into overseas markets, and attractive valuations, which still have significant investment potential in the future. Since the beginning of this year, the stock prices of many innovative drug companies have risen significantly, with individual stocks such as ShuTaiShen, RongChangBio, AngLiKang, and MaiWeiBio seeing gains of over 100% year-to-date. At the same time, Chinese innovative drug companies have also been receiving intensive research visits from foreign institutions. Wind data shows that since the second half of the year, BeiGene has been visited by 53 foreign institutions. In the research list for BeiGene in August, the names of foreign institutions such as Deutsche Bank, BlackRock Fund, Paris Asset Management, HanYa Investment, and Huili Fund appeared.